<DOC>
	<DOCNO>NCT01577368</DOCNO>
	<brief_summary>The main objective verify administration piperacillin / tazobactam administer continuous infusion treat complicate infection know suspected nosocomial isolation Pseudomonas aeruginosa superior efficacy 30 % high dose administer conventional short infusion . The secondary objective compare follow variable : - Microbiological response 3 day start treatment - Time microbiological cure - Clinical response 3 day start treatment - Time achieve defervescence - To examine relationship pharmacokinetic variable parameter efficacy safety - To test hypothesis continuous infusion maintains adequate plasma drug level compare level achieve intermittent administration . - Cost-effectiveness analysis - Occurrence adverse effect To end , design multicenter , randomize , control , double blind , compare form administration patient complicate nosocomial infection without isolation Pseudomonas aeruginosa . Patients candidate inclusion classify accord APACHE II isolation Pseudomonas aeruginosa . Subsequently randomize receive piperacillin-tazobactam continuous infusion short . Primary endpoint measure ultimate effectiveness treatment variable high efficiency , safety , pharmacokinetic pharmacoeconomic .</brief_summary>
	<brief_title>Piperacillin-Tazobactam Continuous Versus Intermittent Infusion Pseudomonas Aeruginosa</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<criteria>Complicated Nosocomial Pseudomonas Aeruginosa Infection Suspected Infection &gt; 18 year &gt; 40 kg Negative pregnancy test woman within fertile period Informed consent signature Life expectancy &lt; 72 hr Central Nervous System ( CNS ) infection Ventilatorassociated pneumonia Severe Neutropenia ( &lt; 500 cells/ml ) Acinetobacter baumannii extend spectrum beta lactamase ( ESBL ) suspect infection Cystic fibrosis Shock Creatinine clearance &lt; 20 ml/min Dialysis hemoperfusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Pseudomonas</keyword>
	<keyword>Piperacillin</keyword>
	<keyword>Beta-lactams</keyword>
	<keyword>Continuous infusion</keyword>
	<keyword>Intermittent infusion</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>